/GZPHF

GZPHF Stock - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Q: What is the analyst price target for GZPHF?

Analyst price target information is not currently available for GZPHF.

Q: What is GZPHF's market cap?

Market capitalization information is not currently available for GZPHF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$2.34+0.00%

+$0.00 (+0.00%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.57

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GZPHF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.32

52W High$2.88

52W Low$2.14

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$74.99B	$75.52B	$70.79B	$69.01B	$61.67B
Gross Profit	$12.52B	$14.19B	$13.28B	$13.23B	$10.44B
Gross Margin	16.7%	18.8%	18.8%	19.2%	16.9%
Operating Income	$3.60B	$5.12B	$5.07B	$4.79B	$3.67B
Net Income	$2.84B	$4.06B	$3.97B	$3.72B	$2.92B
Net Margin	3.8%	5.4%	5.6%	5.4%	4.7%
EPS	$1.74	$2.49	$2.44	$2.29	$1.79

Company Overview

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Visit Website

Earnings History & Surprises

GZPHF

Beat Rate

69%

Last 13 quarters

Avg Surprise

+20.5%

EPS vs Estimate

Beats / Misses

9/4

Last 12 quarters

Latest EPS

$0.01

Q4 2025

EPS Surprise History

Q1 24

No data

Q2 24

+71.8%

$0.17vs$0.10

Q3 24

No data

Q4 24

-16.7%

$0.05vs$0.06

Q4 24

No data

Q2 25

+103.0%

$0.15vs$0.08

Q2 25

-5.1%

$0.06vs$0.06

Q4 25

-84.1%

$0.01vs$0.06

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 29, 2026	—	—	—	—
Q1 2026	Mar 13, 2026	—	—	—	—
Q4 2025	Oct 28, 2025	$0.06	$0.01	-84.1%	✗ MISS
Q2 2025	Jun 30, 2025	$0.06	$0.06	-5.1%	✗ MISS
Q2 2025	Apr 29, 2025	$0.08	$0.15	+103.0%	✓ BEAT
Q4 2024	Dec 31, 2024	—	$-0.03	—	—
Q4 2024	Oct 25, 2024	$0.06	$0.05	-16.7%	✗ MISS
Q3 2024	Aug 30, 2024	—	$0.05	—	—
Q2 2024	May 30, 2024	$0.10	$0.17	+71.8%	✓ BEAT
Q1 2024	Jan 26, 2024	—	$0.02	—	—
Q3 2023	Sep 30, 2023	$0.08	$0.08	+9.6%	✓ BEAT
Q2 2023	Jun 30, 2023	$0.07	$0.08	+4.9%	✓ BEAT
Q1 2023	Mar 17, 2023	$0.37	$0.30	-18.9%	✗ MISS
Q4 2022	Dec 31, 2022	—	$0.04	—	—
Q4 2022	Oct 25, 2022	$0.41	$0.54	+31.7%	✓ BEAT
Q3 2022	Aug 19, 2022	$0.37	$0.48	+29.7%	✓ BEAT
Q2 2022	Apr 26, 2022	$0.65	$1.11	+70.8%	✓ BEAT
Q4 2021	Dec 31, 2021	—	$0.04	—	—
Q4 2021	Oct 26, 2021	$0.38	$0.50	+31.6%	✓ BEAT
Q3 2021	Aug 18, 2021	$0.39	$0.54	+38.5%	✓ BEAT

Frequently Asked Questions about GZPHF

What is GZPHF's current stock price?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) is currently trading at $2.34 per share. The stock has moved +0.00% today.

What is the analyst price target for GZPHF?

No analyst price targets are currently available for this stock.

What sector is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is GZPHF's market cap?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has a market capitalization of $5.93 billion, making it a mid-cap company.

Does GZPHF pay dividends?

No, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited does not currently pay a dividend to shareholders.